BIOLASE, Inc.

OTCPK:BIOL.Q Stock Report

Market Cap: US$274.5k

BIOLASE Management

Management criteria checks 4/4

BIOLASE's CEO is John Beaver, appointed in Feb 2021, has a tenure of 3.83 years. total yearly compensation is $420.69K, comprised of 89.1% salary and 10.9% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $0.91. The average tenure of the management team and the board of directors is 3.7 years and 3.3 years respectively.

Key information

John Beaver

Chief executive officer

US$420.7k

Total compensation

CEO salary percentage89.1%
CEO tenure3.8yrs
CEO ownership0.0003%
Management average tenure3.7yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Biolase partners with dental speciality programs across U.S.

Aug 31

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

Jul 21

BIOLASE amends senior secured term loan with SWK Funding

Jul 01

BIOLASE: Bad News Across The Board - Sell

Mar 21

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Feb 24
Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Jan 11

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Nov 24

CEO Compensation Analysis

How has John Beaver's remuneration changed compared to BIOLASE's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$16m

Jun 30 2024n/an/a

-US$27m

Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$421kUS$375k

-US$38m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$733kUS$375k

-US$29m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$5mUS$396k

-US$17m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$370kUS$308k

-US$34m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$20m

Mar 31 2020n/an/a

-US$19m

Dec 31 2019US$447kUS$325k

-US$18m

Sep 30 2019n/an/a

-US$21m

Jun 30 2019n/an/a

-US$20m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$629kUS$325k

-US$22m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$22m

Dec 31 2017US$566kUS$75k

-US$21m

Compensation vs Market: John's total compensation ($USD420.69K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Beaver (63 yo)

3.8yrs

Tenure

US$420,692

Compensation

Mr. John R. Beaver has been the Chief Executive Officer and President of BIOLASE, Inc. since February 23, 2021 and has been its Director since March 2021. Mr. Beaver served as the Chief Financial Officer s...

Leadership Team

NamePositionTenureCompensationOwnership
John Beaver
President3.8yrsUS$420.69k0.00033%
$ 0.9
Jennifer Bright
Chief Financial Officer3.7yrsUS$361.13k0.00043%
$ 1.2
Steven Sandor
Chief Operating Officer2.4yrsUS$341.54k0.00054%
$ 1.5
Michael Carroll
Corporate Secretaryno datano datano data

3.7yrs

Average Tenure

52.5yo

Average Age

Experienced Management: BIOL.Q's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Beaver
President3.8yrsUS$420.69k0.00033%
$ 0.9
Jonathan Lord
Independent Chairman of the Board10.3yrsUS$112.50k0.0025%
$ 6.9
Kathleen O'Loughlin
Independent Director3.3yrsUS$78.38k0%
$ 0
Martha Somerman
Independent Director3.3yrsUS$80.87k0%
$ 0
Kenneth Yale
Independent Director2.7yrsUS$78.38k0.0011%
$ 3.1

3.3yrs

Average Tenure

69yo

Average Age

Experienced Board: BIOL.Q's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:09
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BIOLASE, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities